Skip to main content
SpringerLink
Log in

Is pamidronate effective in preventing chemotherapy-induced bone loss?

  • Practice Point
  • Published:

From Nature Clinical Practice Endocrinology & Metabolism

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Shapiro CL et al. (2001) Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 19: 3306–3311

    Article  CAS  Google Scholar 

  2. Goodwin PJ et al. (1999) Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol 17: 2365–2370

    Article  CAS  Google Scholar 

  3. Shapiro CL et al. (2005) Baseline bone mineral density of the total lumbar spine may predict for chemotherapy-induced ovarian failure. Breast Cancer Res Treat 90: 41–46

    Article  CAS  Google Scholar 

  4. Shapiro CL (2005) Aromatase inhibitors and bone loss: risks in perspective. J Clin Oncol 23: 4847–4849

    Article  CAS  Google Scholar 

  5. Lonning PE et al. (2005) Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 23: 5126–5137

    Article  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Vicky Heath, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Associate Professor of Medicine in the Division of Hematology and Oncology,

    Charles L Shapiro

  2. Director of Breast Medical Oncology at the Ohio State University Medical Center, Columbus, OH, USA

    Charles L Shapiro

Authors
  1. Charles L Shapiro
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Charles L Shapiro.

Ethics declarations

Competing interests

CLL Shapiro is a Consultant for Novartis and holds an Honorarium from Pfizer. He has research support from Sanofi-Aventis, Pfizer, Genentech, and Roche.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shapiro, C. Is pamidronate effective in preventing chemotherapy-induced bone loss?. Nat Rev Endocrinol 1, 78–79 (2005). https://doi.org/10.1038/ncpendmet0048

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpendmet0048

  • Springer Nature Limited

Search

Navigation